Short-acting non-depolarising neuromuscular blocker
Mivacurium
Brand names: Mivacron
Adult dose
Dose: 0.07–0.15 mg/kg IV bolus, then 8–10 microgram/kg/min infusion
Route: IV
Frequency: per induction
Clinical pearls
- Short procedures; reversible with neostigmine/sugammadex doesn't bind benzylisoquinoliniums
- Slow IV bolus to reduce histamine release
Contraindications
- Plasma cholinesterase deficiency / atypical
- Hypersensitivity
- Severe asthma (caution)
Side effects
- Histamine release (hypotension, flushing)
- Prolonged paralysis in cholinesterase deficiency
- Bronchospasm
Interactions
- Aminoglycosides (potentiation)
- Magnesium
- Volatile anaesthetics
Monitoring
- Train-of-four
- BP
Reference: BNF; AAGBI; https://bnf.nice.org.uk/drugs/mivacurium/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Train-of-Four (TOF) Neuromuscular Monitoring · Neuromuscular Blockade
- MAGGIC Heart Failure Risk Score · Heart Failure
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- New Ballard Score — Gestational Age Assessment · Gestational Age
- MGFA Clinical Classification for Myasthenia Gravis · Neuromuscular
- Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale · Neuromuscular